• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    3/24/23 1:30:41 PM ET
    $APTX
    $BLCM
    $CCM
    $CDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APTX alert in real time by email

    Gainers

    • electroCore (NASDAQ:ECOR) shares increased by 27.9% to $5.47 during Friday's regular session. As of 13:30 EST, electroCore's stock is trading at a volume of 91.3K, which is 434.3% of its average full-day volume over the last 100 days. The company's market cap stands at $25.9 million.
    • Concord Medical Services (NYSE:CCM) shares rose 22.72% to $1.35. The company's market cap stands at $58.6 million.
    • Vicarious Surgical (NYSE:RBOT) stock moved upwards by 20.03% to $1.8. As of 13:30 EST, this security is trading at a volume of 1.4 million shares, making up 378.4% of its average full-day volume over the last 100 days. The company's market cap stands at $226.7 million.
    • Virios Therapeutics (NASDAQ:VIRI) shares rose 19.61% to $0.37. Trading volume for this security as of 13:30 EST is 1.3 million, which is 357.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million.
    • Vaccitech (NASDAQ:VACC) shares moved upwards by 17.11% to $2.53. As of 13:30 EST, Vaccitech's stock is trading at a volume of 812.3K, which is 1535.0% of its average full-day volume over the last 100 days. The company's market cap stands at $94.3 million. As per the news, the Q4 earnings report came out today.
    • ProKidney (NASDAQ:PROK) shares moved upwards by 17.07% to $12.82. The current volume of 165.1K shares is 85.0% of ProKidney's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $788.9 million.

    Losers

    • SQZ Biotechnologies (NYSE:SQZ) stock fell 29.9% to $0.56 during Friday's regular session. SQZ Biotechnologies's stock is trading at a volume of 1.6 million shares as of 13:30 EST. This is 518.5% of its average full-day volume over the last 100 days. The company's market cap stands at $16.5 million. The company's, Q4 earnings came out 2 days ago.
    • Aptinyx (NASDAQ:APTX) shares fell 17.66% to $0.15. Trading volume for Aptinyx's stock is 25.5 million as of 13:30 EST. This is 1083.2% of its average full-day volume over the last 100 days. The company's market cap stands at $9.9 million.
    • Cidara Therapeutics (NASDAQ:CDTX) stock declined by 16.79% to $1.19. As of 13:30 EST, this security is trading at a volume of 5.7 million shares, making up 191.2% of its average full-day volume over the last 100 days. The company's market cap stands at $98.4 million. As per the news, the Q4 earnings report came out yesterday.
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) stock decreased by 15.73% to $0.25. Bellicum Pharmaceuticals's stock is trading at a volume of 325.2K shares as of 13:30 EST. This is 364.0% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million.
    • Midatech Pharma (NASDAQ:MTP) stock fell 14.15% to $0.3. Trading volume for this security as of 13:30 EST is 92.4K, which is 176.7% of its average full-day volume over the last 100 days. The company's market cap stands at $2.0 million.
    • NuCana (NASDAQ:NCNA) shares fell 13.29% to $1.24. Trading volume for NuCana's stock is 212.6K as of 13:30 EST. This is 162.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $64.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APTX
    $BLCM
    $CCM
    $CDTX

    CompanyDatePrice TargetRatingAnalyst
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    Cidara Therapeutics Inc.
    $CDTX
    10/16/2025$190.00Overweight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    10/10/2025$200.00Overweight
    Analyst
    ProKidney Corp.
    $PROK
    6/30/2025$1.00Neutral → Underperform
    BofA Securities
    Cidara Therapeutics Inc.
    $CDTX
    6/18/2025$41.00Buy
    H.C. Wainwright
    More analyst ratings

    $APTX
    $BLCM
    $CCM
    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,840 worth of shares (1,000 units at $4.84), increasing direct ownership by 0.34% to 292,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/3/25 7:00:20 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Errico Thomas J. bought $67,050 worth of shares (15,000 units at $4.47), increasing direct ownership by 6% to 281,401 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/13/25 6:05:11 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APTX
    $BLCM
    $CCM
    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore's gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder ("PTSD")

    ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD. The study entitled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder," will be led by Danielle DeSouza MSc, PhD, VP of Research at Acacia Clinics ("the Investigator"). The study w

    1/21/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million

    Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities ("Total Cash") balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today provided select unaudited preliminary financial guidance for the full year and fourth quarter of 2025. Financial GuidancePreliminary unaudited financial guidance for the full year and fourth quarter

    1/20/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

    Vicarious Surgical (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess syst

    1/12/26 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $APTX
    $BLCM
    $CCM
    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Sachs Adam David sold $1,967 worth of shares (942 units at $2.09), decreasing direct ownership by 2% to 46,943 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:59:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Technology Officer Khalifa Sammy sold $1,571 worth of shares (754 units at $2.08), decreasing direct ownership by 2% to 32,869 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:58:35 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Executive Officer Goldberger Daniel S was granted 46,375 shares, increasing direct ownership by 16% to 338,940 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    1/28/26 4:30:05 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APTX
    $BLCM
    $CCM
    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Cidara Therapeutics from Outperform to Sector Perform

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded Cidara Therapeutics from Overweight to Equal-Weight

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $BLCM
    $CCM
    $CDTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by ProKidney Corp.

    SCHEDULE 13G - PROKIDNEY CORP. (0001850270) (Subject)

    2/12/26 2:11:38 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vicarious Surgical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    2/2/26 4:30:35 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    ProKidney Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - PROKIDNEY CORP. (0001850270) (Filer)

    2/2/26 4:04:49 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $BLCM
    $CCM
    $CDTX
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $APTX
    $BLCM
    $CCM
    $CDTX
    Financials

    Live finance-specific insights

    View All

    Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will now report financial results for the third quarter ended September 30, 2025 after the market closes on Wednesday, November 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 623856. A live and archived webcast of the event will be available at ht

    11/6/25 6:13:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to JanssenBARDA award to support expanded manufacturing and clinical development of CD388FDA granted Breakthrough Therapy designation to CD388Conference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak® platform

    11/6/25 4:07:08 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    electroCore Announces Third Quarter 2025 Financial Results

    Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue

    11/5/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APTX
    $BLCM
    $CCM
    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $BLCM
    $CCM
    $CDTX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care